Target Information

Target General Infomation
Target ID
T78114
Former ID
TTDI02050
Target Name
CD55
Gene Name
CD55
Synonyms
Complement decayaccelerating factor; CD55
Target Type
Clinical Trial
Disease Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Gastric cancer [ICD9: 151; ICD10: C16]
Glioblastoma multiforme [ICD9: 191; ICD10: C71]
Function
This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. {ECO:0000269|PubMed:7525274}.
BioChemical Class
Receptor of complement activation
UniProt ID
P08174
Sequence
MTVARPSVPAALPLLGELPRLLLLVLLCLPAVWGDCGLPPDVPNAQPALEGRTSFPEDTV
ITYKCEESFVKIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFP
VGTVVEYECRPGYRREPSLSPKLTCLQNLKWSTAVEFCKKKSCPNPGEIRNGQIDVPGGI
LFGATISFSCNTGYKLFGSTSSFCLISGSSVQWSDPLPECREIYCPAPPQIDNGIIQGER
DHYGYRQSVTYACNKGFTMIGEHSIYCTVNNDEGEWSGPPPECRGKSLTSKVPPTVQKPT
TVNVPTTEVSPTSQKTTTKTTTPNAQATRSTPVSRTTKHFHETTPNKGSGTTSGTTRLLS
GHTCFTLTGLLGTLVTMGLLT
Drugs and Mode of Action
Drug(s) Coxsackievirus A21 Drug Info Phase 2 Glioblastoma multiforme [528759]
PAT-SC1 Drug Info Phase 1/2 Gastric cancer [547138]
Onyvax-105 Drug Info Discontinued in Phase 1 Colorectal cancer [546205]
Inhibitor Coxsackievirus A21 Drug Info [528759]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Complement and coagulation cascades
Hematopoietic cell lineage
Viral myocarditis
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
FSH Signaling Pathway
TGF_beta_Receptor Signaling Pathway
Reactome Class B/2 (Secretin family receptors)
Regulation of Complement cascade
WikiPathways Complement and Coagulation Cascades
Complement Activation, Classical Pathway
Human Complement System
GPCR ligand binding
Complement cascade
References
Ref 528759Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41.
Ref 546205Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006889)
Ref 547138Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013314)
Ref 526950Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72.
Ref 528759Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41.
Ref 532641Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep. 2014 Mar;31(3):1059-66.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.